Influence of atrial fibrillation on plasma von Willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure

被引:29
|
作者
Freestone, Bethan [1 ]
Gustasson, Finn
Chong, Aun Yeong [1 ]
Corell, Pernille [2 ]
Kistorp, Caroline [3 ]
Hildebrandt, Per [4 ]
Lip, Gregory Y. H. [1 ]
机构
[1] City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7HQ, W Midlands, England
[2] Frederiksberg Univ Hosp, Dept Cariol & Endocrinol E, Frederiksberg, Denmark
[3] Herlev Univ Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark
[4] Roskilde Univ Hosp, Dept Med, Roskilde, Denmark
关键词
atrial fibrillation; heart failure; N-terminal pro B-type natriuretic peptide; von Willebrand factor;
D O I
10.1378/chest.07-2557
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Endothelial dysfunction is present in patients with heart failure (HF) due to left ventricular systolic dysfunction, as well as in patients with atrial fibrillation (AF) who have normal cardiac function. it is unknown whether AF influences the degree of endothelial dysfunction in patients with systolic HF. Methods: We measured levels of plasma von Willebrand factor (vWF) and E-selectin (as indexes of endothelial damage/dysfunction and endothelial activation, respectively; both enzyme-linked immunosorbent assay) in patients with AF and HF (AF-HF), who were compared to patients with sinus rhythm and HF (SR-HF), as well as in age-matched, healthy, control subjects. We also assessed the relationship of vWF and E-selectin to plasma N-terminal pro B-type natriuretic peptide (NTpro-BNP), a marker for HF severity and prognosis. Results: One hundred ninety patients (73% men; mean age, 69.0 +/- 10.1 years [+/- SD]) with systolic HF were studied, who were compared to 117 healthy control subjects: 52 subjects (27%) were in AF, while 138 subjects (73%) were in sinus rhythm. AF-HF patients were older than SR-HF patients (p = 0.046), but left ventricular ejection fraction and New York Heart Association class were similar. There were significant differences in NT-proBNP (p < 0.0001) and plasma vWF (p = 0.003) between patients and control subjects. On Tukey post hoe analysis, AF-HF patients had significantly increased NT-proBNP (p < 0.001) and vWF (p = 0.0183) but not E-selectin (p = 0.071) levels when compared to SR-HF patients. On multivariate analysis, the presence of AF was related to plasma vWF levels (p = 0.018). Plasma vWF was also significantly correlated with NT-proBNP levels (Spearman r = 0.139; p = 0.0117). Conclusions: There is evidence of greater endothelial damage/dysfunction in AF-HF patients when compared to SR-HF patients. The clinical significance of this is unclear but may have prognostic value.
引用
收藏
页码:1203 / 1208
页数:6
相关论文
共 50 条
  • [1] N-Terminal B-type Natriuretic Peptide in Heart Failure
    Richards, Arthur Mark
    HEART FAILURE CLINICS, 2018, 14 (01) : 27 - +
  • [2] Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: The Frederiksberg heart failure study
    Chong, Aun Yeong
    Freestone, Bethan
    Lim, Hoong Sern
    Kistorp, Caroline
    Gustafsson, Finn
    Hildebrandt, Per
    Lip, Gregory Y. H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 119 (01) : 80 - 82
  • [3] Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation
    Kristensen, Soren Lund
    Jhund, Pardeep S.
    Mogensen, Ulrik M.
    Rorth, Rasmus
    Abraham, William T.
    Desai, Akshay
    Dickstein, Kenneth
    Rouleau, Jean L.
    Zile, Michael R.
    Swedberg, Karl
    Packer, Milton
    Solomon, Scott D.
    Kober, Lars
    McMurray, John J. V.
    CIRCULATION-HEART FAILURE, 2017, 10 (10)
  • [4] B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are comparably useful for disease monitoring in heart failure
    Hammerer-Lercher, A
    Pölzl, G
    Falkensammer, G
    Ludwig, W
    Hügel, H
    Puschendorf, B
    Pachinger, O
    Mair, J
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 106 (03) : 415 - 417
  • [5] Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels
    Carrasco-Sanchez, Francisco J.
    Perez-Calvo, Juan I.
    Morales-Rull, Jose L.
    Galisteo-Almeda, Luis
    Paez-Rubio, Inmaculada
    Baron-Franco, Bosco
    Aguayo-Canela, Mariano
    Pujol-De la llave, Emilio
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2014, 15 (02) : 115 - 121
  • [6] Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases
    Da-Rong Pu
    Jun R. Chiong
    Qi-chang Zhou
    Heart Failure Reviews, 2010, 15 : 293 - 304
  • [7] Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases
    Pu, Da-Rong
    Chiong, Jun R.
    Zhou, Qi-chang
    HEART FAILURE REVIEWS, 2010, 15 (04) : 293 - 304
  • [8] N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
    Kristensen, Soren L.
    Mogensen, Ulrik M.
    Jhund, Pardeep S.
    Rorth, Rasmus
    Anand, Inder S.
    Carson, Peter E.
    Desai, Akshay S.
    Pitt, Bertram
    Pfeffer, Marc A.
    Solomon, Scott D.
    Zile, Michael R.
    Kober, Lars
    McMurray, John J. V.
    CIRCULATION-HEART FAILURE, 2019, 12 (03)
  • [9] Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation
    Hofer, Felix
    Pailer, Ulrike
    Sulzgruber, Patrick
    Gerges, Christian
    Winter, Max-Paul
    Giugliano, Robert P.
    Gottsauner-Wolf, Michael
    Hulsmann, Martin
    Kazem, Niema
    Koller, Lorenz
    Schonbauer, Robert
    Niessner, Alexander
    Hengstenberg, Christian
    Zelniker, Thomas A.
    ESC HEART FAILURE, 2022, 9 (04): : 2367 - 2377
  • [10] Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation
    Voors, Adriaan A.
    Lam, Carolyn S. P.
    CIRCULATION-HEART FAILURE, 2017, 10 (10)